Drug delivery in OA
Brief Overview of Osteoarthritis Current treatments for
Primary OA or Idiopathic: Osteoarthritis symptoms
o of no known cause or disability-relieving
Secondary OA: Nutraceuticals
o Post traumatic Pain relief
o Congenital Non-steroidal anti-
o Malposition inflammatory
o Postoperative drugs (NSAIDS)
o Metabolic Corticosteroid
intra-articular joint
o Endocrine disorders
injections
o Aseptic osteonecrosis
Physical therapy
8.75 million between the age of 45-75 + Life-style changes
4.11 million OA of the knee predicted to escalate to 8 million by 2035 e.g. weight loss
Ranked 10th cause of Years lost due to disability in Europe&Americas (WHO)
Tissues, molecular targets and current therapeutics in osteoarthritis
This picture shows the different targets for different tissues
At the anatomical level, may want to target the bone, Drug Delivery
cartilage, ligaments and synovial membrane potentially Definition: Drug delivery is the
At the cellular level: chondrocytes, synovial cells, infiltrating process of administering
t cells, infiltrating macrophages pharmaceutical compounds to
Molecular targets that have been study: inflammation targets, achieve therapeutic effect in a
targets of repair and remodelling, target pain generating controlled and targeted manner.
pathways Objective: Optimize drug
Statins: efficacy, minimise side effects,
o emerging therapy and enhance patient compliance.
o thought to supress the inflammatory cytokine activity
in the synovial fluid
o This will decrease enzymes, such as ADAM-TS4/TS5
o Which will potentially slow the progression and loss
of cartilage in OA
antirheumatic drugs
o don’t appear to be effective in OA
Brief Overview of Osteoarthritis Current treatments for
Primary OA or Idiopathic: Osteoarthritis symptoms
o of no known cause or disability-relieving
Secondary OA: Nutraceuticals
o Post traumatic Pain relief
o Congenital Non-steroidal anti-
o Malposition inflammatory
o Postoperative drugs (NSAIDS)
o Metabolic Corticosteroid
intra-articular joint
o Endocrine disorders
injections
o Aseptic osteonecrosis
Physical therapy
8.75 million between the age of 45-75 + Life-style changes
4.11 million OA of the knee predicted to escalate to 8 million by 2035 e.g. weight loss
Ranked 10th cause of Years lost due to disability in Europe&Americas (WHO)
Tissues, molecular targets and current therapeutics in osteoarthritis
This picture shows the different targets for different tissues
At the anatomical level, may want to target the bone, Drug Delivery
cartilage, ligaments and synovial membrane potentially Definition: Drug delivery is the
At the cellular level: chondrocytes, synovial cells, infiltrating process of administering
t cells, infiltrating macrophages pharmaceutical compounds to
Molecular targets that have been study: inflammation targets, achieve therapeutic effect in a
targets of repair and remodelling, target pain generating controlled and targeted manner.
pathways Objective: Optimize drug
Statins: efficacy, minimise side effects,
o emerging therapy and enhance patient compliance.
o thought to supress the inflammatory cytokine activity
in the synovial fluid
o This will decrease enzymes, such as ADAM-TS4/TS5
o Which will potentially slow the progression and loss
of cartilage in OA
antirheumatic drugs
o don’t appear to be effective in OA
